Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879832 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5392232 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6056281 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5406229 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5384869 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL14459057 | 0.91 | CYP1A2 (0.50) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL7432467 | 0.89 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL23355288 | 0.88 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL2592513 | 0.88 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5388086 | 0.88 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION | 2016-01-21 | — | — | US | disclosed |
| US-9220715-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220715-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005051384-A1 | STABILISED PHARMACEUTICAL COMPOSITIONS | PFIZER LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005027975-A1 | COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005025675-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND SEROTONIN / NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
| WO-2004053192-A9 | ORALLY ADMINISTERED DOSAGE FORMS OF FUSED GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY | XENOPORT INC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040162351-A1 | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity | XENOPORT, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040147455-A1 | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof | XENOPORT, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004052360-A1 | PRODRUGS OF FUSED GABA ANALOGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004053192-A1 | ORALLY ADMINISTERED DOSAGE FORMS OF FUSED GABA ANALOG PRODRUGS HAVING REDUCED TOXICITY | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158247-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | CYP1A2 1067/4885ALDH1A1 886/4885USP2 631/4885 |
| US-20160015715-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | CYP1A2 2696/4885ALDH1A1 1653/4885USP2 795/4885 |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | PARK7, PDE7B, PDE7A | CYP1A2 2696/4885ALDH1A1 1653/4885USP2 795/4885 |
| US-20040162351-A1 | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity | GABRB1, GABRB2, GABRB3 | CYP1A2 80/4885ALDH1A1 45/4885USP2 1303/4885 |
| US-20040147455-A1 | Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof | GABRB1, GABRB2, GABRB3 | CYP1A2 245/4885ALDH1A1 380/4885USP2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.